Need help navigating aged care? Explore our support services
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

Treating dementia – drug therapy not the answer

Posted
by DPS

Almost 190,000 Australians have dementia and as Australia’s population ages, dementia becomes a bigger challenge for doctors, their patients and carers.

According to the National Prescribing Service Limited (NPS), there are limited benefits to using cholinesterase inhibitors and memantine drug therapy in the treatment of patients with dementia.

“Research indicates that the benefits of cholinesterase inhibitors and memantine are small.

Some people will not respond and adverse effects are common,” says NPS clinical expert, Education and Quality Assurance program manager, Ms Judith Mackson.

“Because the response rate is low and the effects of cholinesterase inhibitors and memantine are small, if these medicines are to be used, it is imperative that they are monitored in order to objectively assess their effectiveness for the patient.

Anti-psychotics have a very limited role in some of the challenging behaviours of dementia and the risk of cerebrovascular events and all cause mortality increases.

Consequentially, if there are no clear beneficial effects, a trial withdrawal should be attempted, because for many patients symptoms will NOT worsen on withdrawal.

A planned, regular and also opportunistic approach to reviewing medications is recommended not only for people with Alzheimer’s disease, but all older people using medicines,” Ms Mackson said.

She says health professionals need to encourage the use of non-pharmacological strategies at all stages of dementia.

“We know that non-pharmacological strategies can help promote and maintain independence, cognitive function and manage the behavioural and psychological symptoms of dementia.”

“Carers may see medication as the only option, so they will need support and information to help manage their expectations on the effectiveness of medication,” she said.

“Appropriate counselling for carers from health professionals on the limited benefits of drug therapy is key to best practice.

“In addition, carers may need information about the process of withdrawal if there are no clear beneficial effects of the medication.”

The new NPS education program, ‘Treating the symptoms of dementia’  provides information  about how to make informed decisions when working with patients with dementia.

To find out about the education program, visit the NPS website:

www.nps.org.au.

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo